Evidence map›Paper›PMID 36183087›Full record

ArticleBMC infectious diseases2022

Psychometric validation of a chinese version of COVID-19 vaccine hesitancy scale: a cross-sectional study.

Yiman Huang, Yijin Wu, Zhenwei Dai, Weijun Xiao, Hao Wang, Mingyu Si, Wenjun Wang, Xiaofen Gu, Li Ma, Li Li and 5 more

Open access · goldAbstract read
In one paragraph

Article in BMC infectious diseases, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
1.6field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 10 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 7 institutions in 1 country.

Yiman Huang *School of Population Medicine and Public Health, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
Yijin Wu *School of Population Medicine and Public Health, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
Zhenwei DaiSchool of Population Medicine and Public Health, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
Weijun XiaoSchool of Population Medicine and Public Health, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
Hao WangSchool of Population Medicine and Public Health, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
Mingyu SiSchool of Population Medicine and Public Health, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
Wenjun WangSchool of Nursing, Jining Medical University, Jining, Shandong, China.
Xiaofen GuAffiliated Tumor Hospital, Xinjiang Medical University, Urumqi, China.
Li MaSchool of Public Health, Dalian Medical University, Dalian, China.
Li LiDepartment of Clinical Research, The First Affiliated Hospital, Jinan University, Guangzhou, China.
Shaokai ZhangHenan Cancer Hospital, Affiliated Cancer Hospital of Zhengzhou University, Zhengzhou, China.
Chunxia YangDepartment of Epidemiology and Biostatistics, School of Public Health and West China Fourth Hospital, Sichuan University, Chengdu, Sichuan, China.
Yanqin YuSchool of Public Health, Department of Clinical Research, Baotou Medical College, Baotou, China.
Youlin QiaoSchool of Population Medicine and Public Health, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
Xiaoyou SuSchool of Population Medicine and Public Health, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China. suxiaoyou@hotmail.com.ORCID http://orcid.org/0000-0002-4216-2142
Chinese Academy of Medical Sciences & Peking Union Medical College · CNDalian Medical University · CNBaotou Medical College · CNJining Medical University · CNSichuan University · CNXinjiang Medical University · CNZhengzhou University · CN

Funding

Asian Regional Special Cooperation Fund of National Health Commission of the People's Republic of China BLXM01
6 · The paper itself

Abstract

backgroundCOVID-19 vaccines have been administered in many countries; however, a sufficient vaccine coverage rate is not guaranteed due to vaccine hesitancy. To improve the uptake rate of COVID-19 vaccine, it is essential to evaluate the rate of vaccine hesitancy and explore relevant factors in different populations. An urgent need is to measure COVID-19 vaccine hesitancy among different population groups, hence a validated scale for measuring COVID-19 vaccine hesitancy is necessary. The present study aims to validate the COVID-19 vaccine hesitancy scale among different populations in China and to provide a scale measuring COVID-19 vaccine hesitancy with satisfactory reliability and validity.

methodsSelf-reported survey data were collected from different populations in China from January to March 2021. Based on the Parent Attitudes about Childhood Vaccines scale, 15 items were adapted to evaluate the COVID-19 vaccine hesitancy. Exploratory and confirmatory factor analysis were utilized to identify internal constructs of the COVID-19 vaccine hesitancy scale among two randomly split subsets of the overall sample. Reliability was analyzed with the internal consistency, composite reliability, and the test-retest reliability, and validity was analyzed with the criterion validity, convergent validity, and discriminant validity.

resultsA total of 4227 participants completed the survey, with 62.8% being medical workers, 17.8% being students, 10.3% being general population, and 9.1% being public health professionals. The exploratory factor analysis revealed a three-factor structure that explain 50.371% of the total variance. The confirmatory factor analysis showed that models consisting of three dimensions constructed in different populations had good or acceptable fit (CFI ranged from 0.902 to 0.929, RMSEA ranged from 0.061 to 0.069, and TLI ranged from 0.874 to 0.912). The Cronbach's α for the total scale and the three subscales was 0.756, 0.813, 0.774 and 0.705, respectively. Moreover, the COVID-19 vaccine hesitancy scale had adequate test-retest reliability, criterion validity, convergent validity, and discriminant validity.

conclusionsThe COVID-19 vaccine hesitancy scale is a valid and reliable scale for identifying COVID-19 vaccine hesitancy among different population groups in China. Given the serious consequences of COVID-19 vaccine hesitancy, future studies should validate it across regions and time to better understand the application of the COVID-19 vaccine hesitancy scale.

Indexed as

COVID-19VaccinesChildChinaCOVID-19 VaccinesCross-Sectional StudiesHumansPsychometricsReproducibility of ResultsSurveys and QuestionnairesVaccination HesitancyCOVID-19 VaccinesVaccinesCOVID-19ScaleVaccine hesitancyValidation

Identifiers

PMID36183087
PMCPMC9526461
OpenAlexW4298201497

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.